(Wang, Chang)Nov 16, 2026 - Nov 15, 2027 IBEST-OUHC Collaborative Neuroscience Funding for Interdisci BBB-Crossing Lipid Nanoparticles for Stage- Matched mRNA Reprogramming of TBI-Induced Neuroinflammation Role Description: There’s an urgent need to develop treatments throughout the course of traumatic brain injury (TBI) to meet the
brain’s changing therapeutic needs. This project integrates biomedical engineering, pharmaceutical science,
and neuroscience to develop a stage-matched treatment for TBI. We recently developed BBB-crossing lipid
nanoparticles (BLNPs) that can deliver messenger RNA (mRNA) to brain cells. We will now engineer and
identify LNP formulations that perform best at different stages of TBI as the BBB and neurovascular
environment change. These formulations will then deliver a programmed sequence of mRNAs encoding IL-4,
TGF-ß1, and IGF-1, designed to reduce inflammation, promote resolution, and support brain repair,
respectively.
The key engineering innovation is to match both the LNP carrier and its mRNA therapeutic cargoes to the
changing biological stage of TBI, rather than relying on a single treatment. This cross-campus collaboration between OU engineers and OU Harold Hamm Health neuroscientists will generate preliminary data for a new
treatment strategy and future NIH/DOD grant application. Role: Co-PI |
|
P20GM161969 (Tsoikas, Leonidas)May 1, 2026 - Jan 31, 2031 NIH Oklahoma Center For Research Excellence in Sensory Biology Role: Mentor |
|
HT9425-23-1-0517 (Kelly Standifer)Jul 1, 2023 - Jun 30, 2027 USAMRAA CDMRP Neuropeptide modulation of cerebral blood flow to improve neurological and psychological outcomes following TBI in the presence and absence of traumatic stress Role Description: We hypothesize that N/OFQ contributes to disrupted cerebrovascular regulation and ischemia following mild
or moderate TBI, and that modulation N/OFQ activity will prevent or reduce TBI-induced reduction in cerebral
blood flow (CBF), brain ischemia, locomotor deficits, allodynia, anxiety behaviors and memory loss. We also
hypothesize that TBI/PTSD polytrauma exacerbates the outcomes of TBI, including duration and severity of
symptoms. The objectives of this proposal are to 1) test the ability of a NOP receptor partial agonist to reverse
TBI-induced CBF changes; 2) temporally define when ischemia appears in all injury groups using a novel PET
imaging agent and interrogate its relationship to plasma and brain N/OFQ levels; 3) test NOP receptor
modulators for their ability to reverse CBF, ischemia and neurosensory and psychological deficits following
moderate TBI +/- PTSD.
Use of the validated controlled cortical impact (CCI) TBI model enables us to directly measure cerebral blood
flow (CBF) since it requires a craniotomy for the TBI. Role: PI |
|
HT9425-23-1-0340 (Standifer, Kelly)Apr 15, 2023 - Apr 14, 2027 USAMRAA CDMRP NOP receptor modulator treatment optimizes cognitive, locomotor and sensory outcomes of mild concussive TBI with and without PTSD Role Description: We will simulate the most common type of human brain injury, mild concussive TBI, using blunt impact to the
intact head in male and female rats. Interrogation of a temporal framework for detection of brain ischemia by
PET imaging with a novel PET tracer that detects ischemic tissue is part of Aim 1. Assessment of ischemia is
a primary outcome, to correlate with neurological scores, serum and brain N/OFQ (quantified by RIA) and
NOP receptor level and affinity in brain tissue following TBI . Aim 2 will analyze the ability of a NOP receptor
partial agonist to mitigate the following primary (ischemia, cognitive and locomotor deficits) and secondary
outcomes (allodynia and anxiety) following TBI alone or TBI + PTSD, in male and female rats. The high
comorbidity of TBI and PTSD puts these patients at higher risk for deficits, and poorer long term health
outcomes and quality of life. Immunohistochemical labeling also will reveal if drug treatment alters N/OFQ
expression patterns 31 days post-TBI or TBI/PTSD, and if it differs in males compared to females. Role: PI |
|
W81XWH-18-2-0044 (Cippitelli, A)Jan 2, 2023 - Mar 1, 2025 DOD CDMRP Evaluation of PPL-138, a NOP/mu partial agonist, for treatment of alcohol abuse in the context of PTSD Role: Site PI |
|
(Awasthi, V.)Dec 9, 2017 - Aug 30, 2022 DOD Pharmacotherapy of Traumatic Brain Injury Accompanied by Hemorrhagic Shock Role: Co-I |
|
(Standifer, Kelly)Aug 1, 2017 - Jul 31, 2020 OCAST Post-traumatic stress disorder and co-morbid chronic pain: evidence that TNF initiates a sequelae involving Nociceptin/OFQ Role: PI |
|
(Standifer, Kelly)Jan 15, 2011 - Jan 14, 2015 DOD DMRDP Molecular mechanisms of chronic pain and its modulation by posttraumatic stress disorder and Nociceptin/Orphanin FQ, Role: PI |
|
DR080343 (Standifer, Kelly)Jul 1, 2009 - Dec 31, 2010 DOD CDMRP Blockade of nociceptin signaling reduces biochemical, structural and cognitive deficits after traumatic brain injury Role: PI |
|
HR08-152 (Standifer, Kelly)Aug 1, 2008 - Jul 31, 2011 OCAST Orphanin FQ/nociceptin regulates tyrosine hydroxylase expression Role: PI |
|
R01DA017380 (STANDIFER, KELLY M)Apr 16, 2004 - Sep 30, 2009 NIH Cellular mechanisms of ORL1 regulation and cross talk Role: Principal Investigator |
|
ARP (Standifer, Kelly)Jan 1, 2000 - Dec 31, 2003 Texas Higher Education Coordinating Board Cell-specific induction of GRK subtypes mediates opioid receptor cross talk mechanisms Role: PI |
|
ARP (Standifer, Kelly)Jan 1, 2000 Texas Higher Education Coordinating Board Can cannabinoid antagonists block the addictive, but not analgesic, actions of opioids Role: PI |
|
(Standifer, Kelly)Oct 1, 1996 - Sep 30, 1998 AACP New Investigator Program Site specific agents: Tools for the control of epilepsy Role: PI |
|
R29DA010738 (STANDIFER, KELLY M)Apr 1, 1996 - Feb 28, 2002 NIH OPIOID RECEPTOR SIGNAL TRANSDUCTION MECHANISMS Role: Principal Investigator |
|
(Standifer, Kelly)Jul 1, 1995 - Jun 30, 1996 Wendy Will Case Cancer Fund, Inc. k3 opioid receptor signal transduction mechanisms Role: PI |